Baxter International Inc. (NYSE:BAX) Shares Purchased by Amalgamated Bank

Amalgamated Bank lifted its holdings in Baxter International Inc. (NYSE:BAX) by 1.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 100,118 shares of the medical instruments supplier’s stock after acquiring an additional 1,897 shares during the period. Amalgamated Bank’s holdings in Baxter International were worth $3,427,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. CoreFirst Bank & Trust acquired a new stake in shares of Baxter International in the fourth quarter valued at about $26,000. MassMutual Private Wealth & Trust FSB grew its position in Baxter International by 48.1% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 2,021 shares of the medical instruments supplier’s stock valued at $69,000 after acquiring an additional 656 shares in the last quarter. Farther Finance Advisors LLC grew its position in Baxter International by 61.2% in the fourth quarter. Farther Finance Advisors LLC now owns 4,060 shares of the medical instruments supplier’s stock valued at $118,000 after acquiring an additional 1,541 shares in the last quarter. Bruce G. Allen Investments LLC grew its position in Baxter International by 35.2% in the first quarter. Bruce G. Allen Investments LLC now owns 3,546 shares of the medical instruments supplier’s stock valued at $121,000 after acquiring an additional 924 shares in the last quarter. Finally, Parallel Advisors LLC grew its position in Baxter International by 58.7% in the first quarter. Parallel Advisors LLC now owns 4,059 shares of the medical instruments supplier’s stock valued at $139,000 after acquiring an additional 1,502 shares in the last quarter. Institutional investors and hedge funds own 90.19% of the company’s stock.

Baxter International Stock Performance

Shares of NYSE BAX opened at $31.08 on Friday. The company has a current ratio of 2.02, a quick ratio of 1.40 and a debt-to-equity ratio of 1.33. The stock has a 50 day simple moving average of $30.67 and a 200-day simple moving average of $31.22. The company has a market cap of $15.95 billion, a PE ratio of -28.25, a P/E/G ratio of 0.91 and a beta of 0.61. Baxter International Inc. has a 12-month low of $26.25 and a 12-month high of $40.49.

Baxter International (NYSE:BAX) last issued its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.14. The company had revenue of $2.63 billion during the quarter, compared to analyst estimates of $2.59 billion. Baxter International had a negative net margin of 4.71% and a positive return on equity of 17.24%. The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.65 EPS. On average, equities research analysts forecast that Baxter International Inc. will post 2.48 EPS for the current year.

Baxter International Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, July 1st. Stockholders of record on Friday, May 30th were issued a $0.17 dividend. The ex-dividend date of this dividend was Friday, May 30th. This represents a $0.68 annualized dividend and a dividend yield of 2.19%. Baxter International’s dividend payout ratio (DPR) is -61.82%.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Wall Street Zen upgraded Baxter International from a “hold” rating to a “buy” rating in a research note on Sunday, June 22nd. Wells Fargo & Company lowered their price objective on Baxter International from $36.00 to $33.00 and set an “equal weight” rating for the company in a research note on Friday, May 2nd. Barclays raised their price objective on Baxter International from $39.00 to $41.00 and gave the company an “overweight” rating in a research note on Monday, March 10th. Finally, Morgan Stanley lowered their price objective on Baxter International from $30.00 to $28.00 and set an “underweight” rating for the company in a research note on Monday, May 5th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Baxter International presently has an average rating of “Hold” and an average price target of $36.14.

Baxter International Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.